Actavis (ACT) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Actavis (ACT) Price Target Raised to $254 at UBS
August 6, 2014 11:21 AM EDTUBS maintained a Buy rating on Actavis (NYSE: ACT) and raised its price target to $254.00 (from $237.00). The change follows Q2 results.
Analyst Marc Goodman said, "(1) Mgt has aspiration of $20.00 EPS for 2017, which will depend on both new branded and generics product... More
